Comparative analysis of Basiliximab and Alemtuzumab induction therapies in blood type A2-to-B kidney transplantation: Impact on kidney function and de novo donor-specific HLA antibodies

CONCLUSION: The use of Basiliximab as induction immunosuppression in A2-to-B kidney transplant recipients is associated with a lower incidence of de novo HLA DSA formation without significant differences in overall renal function compared to Alemtuzumab.PMID:37949378 | DOI:10.1016/j.trim.2023.101958

Source: Transplant Immunology - November 10, 2023 Category: Transplant Surgery Authors: Tareq Hanouneh Rose Mary Attieh Emily Craver Abdullah Jebrini Mohamed Elrefaei Tambi Jarmi Source Type: research